Holen Sie sich die Stockscreener-App
57.04
1.33%
0.75
Handel nachbörslich:
57.14
0.10
+0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$56.29
Offen:
$56.625
24-Stunden-Volumen:
8.77M
Relative Volume:
0.90
Marktkapitalisierung:
$115.69B
Einnahmen:
$47.44B
Nettoeinkommen (Verlust:
$-7.26B
KGV:
-15.89
EPS:
-3.59
Netto-Cashflow:
$13.80B
1W Leistung:
+2.33%
1M Leistung:
-0.51%
6M Leistung:
+33.77%
1J Leistung:
+13.83%
1-Tages-Spanne:
$56.55
$57.68
1-Wochen-Bereich:
$55.08
$57.68
52-Wochen-Spanne:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.04 | 115.69B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
742.35 | 705.53B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
81.03 | 359.79B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
148.15 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
172.61 | 305.03B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
96.24 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Jim Cramer Says Bristol-Myers Squibb Company (BMY)’s ‘Got The One That Everybody Is Buzzing About’ - Insider Monkey
Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment - Benzinga
Why Is Bristol-Myers Squibb Company (BMY) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
M.E. Allison & CO. Inc. Purchases New Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
HB Wealth Management LLC Raises Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol-Myers Squibb (BMY) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Trust Co. of Vermont Has $2.55 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Says New Schizophrenia Drug Off to Strong Start - MSN
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Avanza Fonder AB Makes New Investment in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Copy of Jim and Mia Cassady Are Bringing Pickleball Centers to Delaware County #2 - BUCKSCO.Today
Bristol-Myers Squibb Company – Consensus ‘hold’ rating and 9.1% Upside Potential - DirectorsTalk Interviews
8,382 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Decker Retirement Planning Inc. - MarketBeat
Eagle Rock Investment Company LLC Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
8,620 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Contravisory Investment Management Inc. - MarketBeat
Earnings Preview: What To Expect From Bristol-Myers Squibb's Report - Barchart
Cobenfy: Bristol Myers Squibb's Answer to Alzheimer's and SchizophreniaNews and Statistics - IndexBox, Inc.
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug - CNBC
Meyer Handelman Co. Decreases Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Radnor Capital Management LLC Has $4.57 Million Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Acropolis Investment Management LLC Has $1.92 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Leerink Partnrs Analysts Lift Earnings Estimates for BMY - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Says New Schizophrenia Drug Off to Strong Start | Company Business News - Mint
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Wright Investors Service Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Stake Raised by Brookstone Capital Management - MarketBeat
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27) - MSN
Bristol Myers Squibb CEO describes new drug for treating schizophrenia - NBC Philadelphia
Bristol-Myers Squibb (BMY) Releases New Investor Presentation - GuruFocus.com
Mid American Wealth Advisory Group Inc. Decreases Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Capital Investment Advisors LLC Has $14.02 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Is Intra-Cellular Therapies Surging On Monday?Intra-Cellular Therapies (NASDAQ:ITCI), Johnson & Johnson (NYSE:JNJ) - Benzinga
Czech National Bank Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors - The Manila Times
Bristol Myers Squibb licenses new CAR T therapy - Investing.com
Retinoblastoma Market Profiles: Segment Size, Growth, - openPR
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Hypercholesterolemia Treatment Market Top PlayersAbbVie, - openPR
West Oak Capital LLC Has $2.28 Million Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture? - Benzinga
Franklin Street Advisors Inc. NC Raises Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Abbvie to record $3.5 bln charge related to schizophrenia drug - Reuters
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference - Benzinga
8 Undervalued Stocks That Just Raised Dividends - Morningstar
How To Put $100 In Your Retirement Fund Each Month With Bristol-Myers Squibb Stock - Yahoo Finance
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries - GlobeNewswire Inc.
International Assets Investment Management LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.22%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):